|1.||Cui, Zhao: 16 articles (12/2015 - 10/2004)|
|2.||Mohan, Chandra: 11 articles (01/2014 - 04/2004)|
|3.||Yamamoto, Tadashi: 10 articles (06/2014 - 10/2003)|
|4.||Borza, Dorin-Bogdan: 10 articles (05/2013 - 05/2002)|
|5.||Zhao, Ming-Hui: 9 articles (12/2015 - 07/2005)|
|6.||Kitching, A Richard: 9 articles (01/2014 - 02/2002)|
|7.||Zhou, Xin J: 9 articles (01/2013 - 04/2004)|
|8.||Pusey, Charles D: 8 articles (04/2013 - 02/2002)|
|9.||Zhao, Juan: 8 articles (09/2011 - 01/2007)|
|10.||Nikolic-Paterson, David J: 7 articles (01/2015 - 01/2003)|
09/15/2009 - "This novel attenuated model allows elucidating the relative contribution of different mediator systems of the immune system to the development of renal injury, and also provides a platform for the assessment of different treatment protocols and evaluation of drugs that ultimately may be beneficial for the treatment of anti-GBM mediated glomerulonephritides."
04/15/2014 - "Galectin-9 ameliorates anti-GBM glomerulonephritis by inhibiting Th1 and Th17 immune responses in mice."
04/01/2009 - "In conclusion, blockade of JNK signaling provides substantial protection against the progression of crescentic anti-GBM glomerulonephritis, which may be, in part, due to inhibition of the macrophage proinflammatory response."
02/01/2003 - "Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis."
05/01/2013 - "In the present study, we sought to establish whether recombinant RPS19 can exert anti-inflammatory effects in a mouse model of anti-GBM (glomerular basement membrane) GN (glomerulonephritis) in which MIF is known to play an important role. "
11/01/1992 - "These results indicate that OB-5 was effective in crescentic-type anti-GBM nephritis and the antinephritic mechanisms of this agent may be due to its ability to inhibit the proliferation or the migration of macrophages and cytotoxic T lymphocytes in the glomeruli."
01/01/2009 - "Anti-GBM antibody nephritis has a poor prognosis, but renal function was maintained for 15 years in this patient, who responded well to the initial treatment. "
03/01/2011 - "This study was performed to demonstrate that combination therapy with a CCR2 antagonist (CA) and an Ang II type 1 receptor blocker (ARB) ameliorated renal injury in the anti-GBM nephritis model. "
12/01/1997 - "In the present study, we have assessed whether preparations of anti-GBM antibody contaminated with different concentrations of endotoxin could influence the severity of glomerular injury in the heterologous phase of nephrotoxic nephritis. "
01/01/1996 - "Antiproteolytic drugs utilized in our studies exert their beneficial effect on autologous anti-GBM nephritis through interference with inflammatory phase of the disease, while sparing its immune induction and mechanisms of coagulation/fibrinolysis."
|3.||Anti-Glomerular Basement Membrane Disease (Goodpasture's Syndrome)
04/01/1988 - "This case illustrates that life-threatening relapse may occur in Goodpasture's syndrome despite a prolonged remission and the disappearance of detectable antiglomerular basement membrane antibody in the circulation."
05/01/2006 - "In this study, we investigated the effect of IA on serum anti-GBM level and evaluated its clinical efficacy in patients with Goodpasture's syndrome. "
08/01/1998 - "Thus, this study underscores cytokine and adhesion molecule requirements for neutrophil mediated injury in lung and kidney caused by anti-GBM, suggesting potential targets for the treatment of Goodpasture's syndrome in humans."
07/01/1995 - "As with recent studies in human anti-GBM disease, there was no evidence for affinity maturation of the anti-GBM response in the serum of any of the animal models. "
01/01/2015 - "Anti-GBM antibody assays were reported as slightly raised; thus, the diagnosis was anti-GBM disease with normal renal function. "
01/01/2015 - "The treatment was rapidly effective with an immediate decrease in anti-GBM titers and proteinuria. "
01/01/2014 - "Urine studies revealed nephrotic range proteinuria and a serological workup was positive for anti-GBM antibody elevation with a value of 91 units (normal: 0-20 units). "
01/01/2014 - "The anti-GBM-GN mice treated with hGSTM2-MSCs exhibited reduced proteinuria and BUN (58% and 59% reduction, respectively) and ameliorated renal pathological damage, compared with control mice. "
06/01/2009 - "iNKT cell-deficient mice (Jalpha18-/-) injected with anti-GBM serum demonstrated worse renal function, increased proteinuria, and greater glomerular and tubular injury compared with similarly treated wild-type mice. "
08/01/2006 - "Proteinuria was similar between wild-type (wt) and EP1-/- NTS groups, thus negating a role for this subtype in modulating the glomerular permeability barrier in this model of anti-GBM NTS. "
05/01/2006 - "IA could remove serum anti-GBM antibody and resolve pulmonary hemorrhage effectively; the efficacy of IA in improving renal function is markedly determined by the severity of renal damage."
10/01/2010 - "In addition, he was also found to have active pulmonary hemorrhage and positive anti-GBM antibody. "
01/01/2007 - "She was diagnosed as having anti-GBM antibody disease because alveolar hemorrhage was absent. "
12/01/1985 - "Diagnostic difficulties occurred in those with anti-GBM-negative pulmonary hemorrhage. "
01/01/1984 - "The anti-GBM did not react with alveolar BM and the patient had no signs of pulmonary hemorrhage. "
|2.||Antineutrophil Cytoplasmic Antibodies (ANCA)
|4.||Immunoglobulin G (IgG)
|6.||Peroxisome Proliferator-Activated Receptors (PPAR)
|7.||Transforming Growth Factor beta (TGF-beta)
|3.||Renal Dialysis (Hemodialysis)